Consuming more protein may protect patients taking anti-obesity drug from muscle loss
2025-07-12
(Press-News.org) SAN FRANCISCO—Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
Losing muscle (or lean mass) is a common side effect of weight loss in adults with obesity and may negatively affect metabolism and bone health. This is because muscle helps control blood sugar after meals and plays an important role in keeping bones strong, according to study lead researcher Melanie Haines, M.D., of Massachusetts General Hospital and Harvard Medical School in Boston, Mass.
Approximately 40% of the weight lost from taking semaglutide—a type of weight-loss medication known as a GLP-1—comes from lean mass, including muscle. It is not yet known who is at highest risk for muscle loss or how it affects blood sugar levels, Haines said.
The researchers studied 40 adults with obesity for three months. Of these patients, 23 were prescribed semaglutide, while 17 followed a diet and lifestyle program for weight loss called Healthy Habits for Life (HHL). The researchers evaluated how their muscle mass changed.
Study participants who were prescribed semaglutide lost more weight than those who participated in the diet and lifestyle program, but the percent of weight loss that was lean mass was similar between the two groups.
After accounting for weight loss, the researchers found that in the semaglutide group, being older, female or eating less protein was linked to greater muscle loss. Also in this group, losing more muscle was linked to less improvement in blood sugar (HbA1c levels).
“Older adults and women may be more likely to lose muscle on semaglutide, but eating more protein may help protect against this,” Haines said. “Losing too much muscle may reduce the benefits of semaglutide on blood sugar control. This means preserving muscle during weight loss with semaglutide may be important to reduce insulin resistance and prevent frailty in people with obesity.”
Haines said that more studies are needed to find the best way to lose fat but keep muscle when using GLP-1 medications.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-07-12
SAN FRANCISCO—People with an underactive thyroid may have an increased risk of developing small intestinal bacterial overgrowth (SIBO), a risk that may be reduced with thyroid hormone treatment, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“We now know that people with hypothyroidism, especially those with autoimmune thyroiditis, are more likely to develop SIBO, but this risk appear to be mitigated in those taking thyroid medications,” said Ruchi Mathur, M.D., Director of the Diabetes Outpatient ...
2025-07-12
SAN FRANCISCO—Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” said Regina Castaneda, ...
2025-07-12
SAN FRANCISCO—Metabolic health factors, including small increases in blood sugar, are the main drivers of change in the reproductive systems and sexual functioning of aging men, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“Although age and testosterone levels have long been considered an impetus for men’s declining sexual health, our research indicates that these changes more closely correlate with modest increases in blood sugar and other metabolic changes,” said Michael Zitzmann, ...
2025-07-12
SAN FRANCISCO—Strong emotional links between children with chronic conditions and their family caregivers suggest that improving parent well-being may directly benefit a child’s overall health and coping mechanisms, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
The study observed children with growth hormone deficiency and their caregivers to better understand the impact that physical or emotional distress can have. Findings suggest that when parents or caregivers of children with growth hormone deficiency report symptoms of stress, anxiety and depression, so does the child they ...
2025-07-12
SAN FRANCISCO—Oxytocin, often called “the love hormone,” may play a protective role in mood disturbances triggered by sleep loss and hormonal shifts during key reproductive transitions like postpartum and menopause, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
Researchers at Brigham and Women’s Hospital and Harvard Medical School studied the combined impact of sleep interruption and estrogen suppression on mood and oxytocin levels in healthy premenopausal women. Their findings suggest that oxytocin may help reduce the negative mood effects brought on by fragmented sleep, which ...
2025-07-12
SAN FRANCISCO—The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
"Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes,” said study author Amanda Kucinskas, ...
2025-07-11
https://doi.org/10.1016/j.apsb.2025.05.003
This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.
Acute liver injury (ALI) serves as a critical precursor and major etiological factor in the progression and ultimate manifestation of various hepatic disorders. The prevention and treatment of ALI is still a serious global challenge. Given the limited therapeutic options for ALI, exploring novel targeted therapeutic agents becomes imperative. The potential therapeutic ...
2025-07-11
https://doi.org/10.1016/j.apsb.2025.05.018
This new article publication from Acta Pharmaceutica Sinica B, discusses how melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1.
A major obstacle in type 2 diabetes mellitus (T2DM) is sleep fragmentation (SF), which negatively affects testicular function. However, the underlying mechanisms remain to be elucidated. This study demonstrated that SF induces testicular damage through a mechanism involving lipid metabolism, ...
2025-07-11
https://doi.org/10.1016/j.apsb.2025.05.013
This new article publication from Acta Pharmaceutica Sinica B, discusses how single-cell RNA sequencing reveals that Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic cells.
Colorectal tumorigenesis generally progresses from adenoma to adenocarcinoma, accompanied by dynamic changes in the tumor microenvironment (TME). A randomized controlled trial has confirmed the efficacy and safety of Shen-Bai-Jie-Du decoction (SBJDD) in preventing colorectal ...
2025-07-11
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b/vol/15/issue/7
Acta Pharmaceutica Sinica B (APSB) was founded with the goal of creating a global high-level forum centred around drug discovery and pharmaceutical research/application. APSB was included by Chemical Abstracts in 2011, accepted by PubMed Central in 2015, indexed by Science Citation Index in 2017 and has evolved to become one of the most important international journals in the field of pharmaceutical sciences.
APSB is a monthly journal, in English, which publishes ...
LAST 30 PRESS RELEASES:
[Press-News.org] Consuming more protein may protect patients taking anti-obesity drug from muscle loss
